Gene: CACNA2D3

55799
HSA272268
calcium voltage-gated channel auxiliary subunit alpha2delta 3
protein-coding
3p21.1-p14.3
Ensembl:ENSG00000157445 MIM:606399 Vega:OTTHUMG00000158580 UniprotKB:Q8IZS8
NC_000003.12
PubMed|SNP Mapped
5   ANCO-SNPs
ND|AD
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
1.063e-1 (AD)  1.753e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs3773586chr3:54974719 (GRCh38.p7)C>Anicotine dependenceSNV(Single Nucleotide Variation)
rs6810058chr3:54857572 (GRCh38.p7)G>Talcohol dependenceSNV(Single Nucleotide Variation)
rs56247223chr3:54608201 (GRCh38.p7)G>Anicotine dependenceSNV(Single Nucleotide Variation)
rs11708620chr3:54337764 (GRCh38.p7)C>Talcohol dependenceSNV(Single Nucleotide Variation)
rs7431992chr3:54319213 (GRCh38.p7)T>Anicotine dependenceSNV(Single Nucleotide Variation)

DNA Methylation

Probe Locus(GRCh37) Gene Region p-val Trait PubMed ID
cg01569984chr3:54353711CACNA2D3Gene body2.773e-5Alcohol use disorders26763658

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
ADAM230.97
ATP2B30.969
GLS20.965
KCNQ50.962
FBXL20.962
RBFOX10.962
L1CAM0.961
DLG30.961
ADD20.96
NMNAT20.959

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
YES1-0.584
MYL3-0.574
RAI14-0.571
HEY2-0.557
RNF135-0.556
REST-0.555
WWTR1-0.553
TFPI2-0.548
COPZ2-0.542
RAB13-0.541

Drugs/Compounds

ID Drug Name Drug Type CAS Num Status Role
DB00381AmlodipineSmall Molecule88150-42-9ApprovedTarget
DB06712NilvadipineSmall Molecule75530-68-6Approved|InvestigationalTarget
DB00421SpironolactoneSmall Molecule52-01-7ApprovedTarget
ID Drug Name Action PubMed
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CACNA2D3 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CACNA2D3 mRNA"27188386
D000082Acetaminophen[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] affects the expression of CACNA2D3 mRNA25607892
D016604Aflatoxin B1Aflatoxin B1 results in decreased methylation of CACNA2D3 gene27153756
D000517alpha-Chlorohydrinalpha-Chlorohydrin results in increased expression of CACNA2D3 protein26597043
D000643Ammonium ChlorideAmmonium Chloride affects the expression of CACNA2D3 mRNA16483693
D000726Androgen Antagonists[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] affects the expression of CACNA2D3 mRNA25607892
C547126AZM551248AZM551248 results in decreased expression of CACNA2D3 mRNA22323515
C095105bexarotene[bexarotene co-treated with Tamoxifen] results in increased expression of CACNA2D3 mRNA17630414
C006780bisphenol A[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] affects the expression of CACNA2D3 mRNA25607892
C006780bisphenol A[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNA2D3 mRNA25607892
C006780bisphenol Abisphenol A results in decreased expression of CACNA2D3 mRNA25181051
C006780bisphenol Abisphenol A results in increased methylation of CACNA2D3 gene28505145
C038091butylparaben[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] affects the expression of CACNA2D3 mRNA25607892
C038091butylparaben[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNA2D3 mRNA25607892
D002118CalciumCACNA2D3 protein results in increased import of Calcium25504062
D003993Dibutyl Phthalate[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] affects the expression of CACNA2D3 mRNA25607892
D003633Dichlorodiphenyl Dichloroethylene[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] affects the expression of CACNA2D3 mRNA25607892
D004051Diethylhexyl Phthalate[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] affects the expression of CACNA2D3 mRNA25607892
C038939enzacamene[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] affects the expression of CACNA2D3 mRNA25607892
C038939enzacamene[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNA2D3 mRNA25607892
C109476epoxiconazole[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] affects the expression of CACNA2D3 mRNA25607892
C069837fullerene C60fullerene C60 results in decreased expression of CACNA2D3 mRNA19167457
D007052IbuprofenIbuprofen affects the expression of CACNA2D3 mRNA17070997
C561695(+)-JQ1 compound(+)-JQ1 compound results in decreased expression of CACNA2D3 mRNA24435446|2479639
D008044Linuron[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] affects the expression of CACNA2D3 mRNA25607892
D008070LipopolysaccharidesLipopolysaccharides results in decreased expression of CACNA2D3 mRNA18192897
D037742Nanotubes, Carbon"Nanotubes, Carbon results in decreased expression of CACNA2D3 mRNA"15585362
C572573N-nitroso-tris-chloroethylurea[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CACNA2D3 mRNA27935865
C118580octylmethoxycinnamate[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] affects the expression of CACNA2D3 mRNA25607892
C118580octylmethoxycinnamate[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in increased expression of CACNA2D3 mRNA25607892
C060836pioglitazone[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of CACNA2D3 mRNA27935865
C045362prochloraz[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] affects the expression of CACNA2D3 mRNA25607892
C035988procymidone[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] affects the expression of CACNA2D3 mRNA25607892
D011441PropylthiouracilPropylthiouracil results in decreased expression of CACNA2D3 mRNA24780913
C116926rofecoxibrofecoxib results in decreased expression of CACNA2D3 mRNA17070997
D012822Silicon DioxideSilicon Dioxide results in decreased expression of CACNA2D3 mRNA22300531
D018038Sodium SeleniteSodium Selenite results in increased expression of CACNA2D3 mRNA18175754
D013629Tamoxifen[bexarotene co-treated with Tamoxifen] results in increased expression of CACNA2D3 mRNA17630414
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of CACNA2D3 mRNA21570461
C012589trichostatin Atrichostatin A results in increased expression of CACNA2D3 mRNA24935251
C015559trimellitic anhydridetrimellitic anhydride results in decreased expression of CACNA2D3 mRNA19042947
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CACNA2D3 mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of CACNA2D3 mRNA25979313
D014635Valproic AcidValproic Acid affects the expression of CACNA2D3 mRNA17292431
D001335Vehicle EmissionsVehicle Emissions results in increased methylation of CACNA2D3 gene25560391
C025643vinclozolin[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] affects the expression of CACNA2D3 mRNA25607892
C025643vinclozolinvinclozolin affects the expression of CACNA2D3 mRNA19015723
C088658zoledronic acidzoledronic acid results in increased expression of CACNA2D3 mRNA24714768

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005244voltage-gated ion channel activity-IEA-  
GO:0005262calcium channel activity-IEA-  
GO:0046872metal ion binding-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0034765regulation of ion transmembrane transport-IEA-  
GO:0070588calcium ion transmembrane transport-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005886plasma membrane-TAS-  
GO:0016021integral component of membrane-IEA-  
KEGG ID KEGG Term
hsa04010MAPK signaling pathway
hsa04260Cardiac muscle contraction
hsa05410Hypertrophic cardiomyopathy (HCM)
hsa05412Arrhythmogenic right ventricular cardiomyopathy (ARVC)
hsa05414Dilated cardiomyopathy
Reactome ID Reactome Term Evidence
R-HSA-112308Presynaptic depolarization and calcium channel openingTAS
R-HSA-112315Transmission across Chemical SynapsesTAS
R-HSA-112316Neuronal SystemTAS
R-HSA-397014Muscle contractionTAS
R-HSA-5576891Cardiac conductionTAS
R-HSA-5576892Phase 0 - rapid depolarisationTAS
R-HSA-5576893Phase 2 - plateau phaseTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
28440896Genome-wide meta-analysis identifies a novel susceptibility signal at CACNA2D3 for nicotine dependence. (2017 Apr 25)Yin XAm J Med Genet B Neuropsychiatr Genet